Filing Analysis
Stablecoin Development Corp amended restrictions on pre-funded warrants issued in October 2025, leading to the immediate cashless exercise by R01 Fund LP and Framework Ventures IV L.P. This resulted in the issuance of approximately 22.6 million shares of common stock.
🚩 Red Flags
- Significant dilution: The issuance of 22.6 million shares represents a substantial increase relative to the total shares outstanding (approx 45% increase in share count).
📋 Key Facts
- Amendments to October 2025 Pre-Funded Warrants occurred on June 12 and June 15, 2026.
- R01 Fund LP and Framework Ventures IV L.P. each received 11,307,300 shares of common stock.
- Total shares issued via cashless exercise: 22,614,600 shares.
- Total shares issued and outstanding as of June 15, 2026: 50,449,780 shares.
- Cashless exercise price resulted in the withholding of 24,720 shares.
Stablecoin Development Corp announced its financial results for the quarter ended March 31, 2026, and provided an update on its digital asset holdings. The company disclosed holding approximately 2.26 billion SKY tokens as of May 14, 2026, which are utilized in on-chain staking activities.
🚩 Red Flags
- High concentration risk in a single digital asset (2.26 billion SKY tokens), which exposes the company to extreme cryptocurrency market volatility.
📋 Key Facts
- Announced results of operations for the quarter ended March 31, 2026.
- Disclosed holding approximately 2.26 billion SKY tokens as of May 14, 2026.
- Engages in on-chain activities, including staking of its SKY token holdings to generate rewards.
Stablecoin Development Corp is restating its FY 2025 financial statements due to a massive accounting error regarding anti-dilution adjustments for pre-funded warrants. The error results in a non-cash increase in net loss from $22.1 million to $630.8 million for the year ended December 31, 2025.
🚩 Red Flags
- Material restatement of financial statements (Item 4.02).
- Massive increase in reported net loss (from $22.1M to $630.8M).
- Recent 1-for-5 reverse stock split (February 20, 2026).
- Extreme dilution event where warrant shares increased by over 20x due to anti-dilution provisions.
📋 Key Facts
- The company will restate audited financial statements for the year ended December 31, 2025, due to an error in accounting for Pre-Funded Warrants issued on October 16, 2025.
- Anti-dilution adjustments triggered by the conversion of Series D and E Preferred Stock increased the number of shares issuable under the warrants from 1,081,082 to 22,664,040.
- The warrant exercise price was adjusted downward from $0.05 to $0.002385.
- The warrant liability as of December 31, 2025, increased from $30.4 million to $639.1 million.
- The company effected a 1-for-5 reverse stock split on February 20, 2026.
- The warrant liability was reclassified to equity as of March 12, 2026, following stockholder approval.
Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals) disclosed its cryptocurrency holdings, reporting a balance of 2.15 billion SKY tokens as of March 31, 2026. The company is actively participating in on-chain staking activities to generate rewards, marking a total pivot from its previous pharmaceutical business model.
🚩 Red Flags
- Radical business model pivot from biotechnology (NovaBay) to cryptocurrency development
- High concentration of corporate assets in a single cryptocurrency (SKY tokens)
- Micro-cap company entering the highly volatile and regulatory-sensitive crypto staking market
📋 Key Facts
- Held approximately 2.15 billion SKY tokens as of March 31, 2026
- Engaged in on-chain activities including staking to earn rewards
- Company was formerly known as NovaBay Pharmaceuticals, Inc. (Ticker: NBY)
- The information was furnished under Item 2.02 regarding results of operations and financial condition
- The new trading symbol is listed as SDEV on the NYSE American
NovaBay Pharmaceuticals is rebranding as Stablecoin Development Corporation (ticker: SDEV) and pivoting its business model toward digital assets. The company has authorized a new 2026 Equity Incentive Plan and granted CEO Michael Kazley over 19.5 million RSUs and PSUs, with performance hurdles tied to stock price and digital asset net asset value.
🚩 Red Flags
- Radical business pivot from pharmaceuticals to digital assets/stablecoins.
- Massive potential dilution: the 2026 Plan's 22.2M share pool is significant for a micro-cap company.
- CEO compensation is heavily concentrated in performance units tied to speculative 'digital asset net asset value' metrics.
- The company is undergoing a complete identity shift which often precedes high volatility or fundamental instability.
📋 Key Facts
- Corporate name change from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation effective April 2, 2026.
- Ticker symbol change from NBY to SDEV, expected to begin trading April 6, 2026.
- Adoption of the 2026 Equity Incentive Plan with an initial share pool of 22,223,927 shares.
- CEO Michael Kazley received 4,118,828 RSUs and 15,445,603 PSUs; PSUs are tied to 'digital asset net asset value hurdles'.
- CEO Michael Kazley will serve with a $0 base salary until January 1, 2027, after which it becomes $200,000.
- CFO Tommy Law entered a new employment agreement with a $200,000 base salary and 300,000 RSUs.
NovaBay Pharmaceuticals is undergoing a radical pivot from biotechnology to cryptocurrency, rebranding as 'Stablecoin Development Corporation' and changing its ticker to 'SDEV'. The company disclosed holdings of 2.06 billion SKY tokens and a new strategic focus as an on-chain holding company.
🚩 Red Flags
- Extreme business model pivot from pharmaceuticals to cryptocurrency/stablecoins.
- Significant concentration of assets in a single digital token (SKY).
- Potential for high volatility and regulatory risk associated with the new stablecoin-focused strategy.
📋 Key Facts
- Company name changing to 'Stablecoin Development Corporation' expected April 3, 2026.
- Ticker symbol changing from 'NBY' to 'SDEV' effective April 3, 2026.
- Reported holdings of approximately 2.06 billion SKY tokens as of March 16, 2026.
- The company is engaging in on-chain activities including staking and a strategic investment transaction.
- The pivot represents a shift to an 'on-chain holding company strategy'.
NovaBay Pharmaceuticals stockholders approved a massive increase in authorized common stock from 1.5 billion to 5 billion shares and the issuance of over 843 million shares related to prior private placements. The company also adopted a new 2026 Equity Incentive Plan and removed the prohibition on stockholder action by written consent.
🚩 Red Flags
- Massive increase in authorized shares (3.33x increase to 5 billion shares) suggests extreme future dilution.
- Significant immediate dilution from the approval to issue over 843 million shares via warrant exercises.
- Removal of prohibition on stockholder action by written consent can sometimes lead to hostile governance maneuvers.
📋 Key Facts
- Authorized common stock increased from 1,500,000,000 to 5,000,000,000 shares.
- Approved issuance of 837,696,130 shares of Common Stock upon exercise of pre-funded warrants from a January 16, 2026, private placement.
- Approved issuance of 5,405,406 shares of Common Stock upon exercise of pre-funded warrants from an October 16, 2025, private placement.
- Adopted the 2026 Equity Incentive Plan.
- Amended the Certificate of Incorporation to remove the prohibition against stockholder action by written consent and provide officer exculpation.
NovaBay Pharmaceuticals executed a 1-for-5 reverse stock split effective February 20, 2026 at 4:15 PM ET, with split-adjusted trading beginning February 23, 2026 on NYSE American. Critically, the authorized share count remains unchanged at 1.5 billion shares, dramatically increasing the company's capacity for future dilutive issuances relative to the reduced outstanding share count.
🚩 Red Flags
- Reverse stock split (1-for-5) — a classic distress signal in micro-caps, typically undertaken to maintain exchange minimum bid price compliance
- Authorized share count unchanged at 1.5 billion despite 5:1 reduction in outstanding shares — this massively expands the ratio of authorized-to-outstanding shares, creating enormous dilution capacity
- Multiple 8-K items filed simultaneously (3.03, 5.03, 9.01) — severity escalator per guidelines
- NYSE American listing suggests the company was likely at risk of non-compliance with minimum share price requirements
- No mention of any accompanying business improvement or strategic rationale — the split appears purely defensive
📋 Key Facts
- 1-for-5 reverse stock split effective February 20, 2026 at 4:15 PM ET
- Board approved the split ratio on February 11, 2026; stockholder approval obtained at annual meeting on October 16, 2025
- Authorized shares remain unchanged at 1,500,000,000 — no proportional reduction
- No fractional shares issued; holders received an additional whole share in lieu of fractional shares
- Split-adjusted trading begins February 23, 2026 on NYSE American under unchanged ticker 'NBY'
- New CUSIP number: 66987P 508
- Par value remains $0.01 per share
- Filing signed by CFO Tommy Law